1 results match your criteria: "Italy (L. Manotta); and Humanitas Research Hospital[Affiliation]"
Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
Circulation
July 2014
From Medizinische Klinik II, Kardiologie und Angiologie, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Ruhr Universität Bochum, Bochum, Germany (A.K.); Azienda Ospedaliero Universitaria S. Maria della Misericordia, Udine, Italy (A.P.); Hospital General Universitario Gregorio Marañón, Madrid, Spain (A.A.); Azienda Ospedaliera Niguarda Ca' Granda, Milano, Italy (M.L.); Hospital de Txagorritxu, Vitoria (Álava), Spain (J.B.M.F.); College of Medicine, King Saud University, Riyadh, Saudi Arabia (A.H.); MSWiA Hospital, Bialystok, Poland (M. Gulaj); St. Antonius Ziekenhuis Hospital, Nieuwegein, Netherlands (M.C.E.F.W.); Medtronic Clinical Research Institute, Rome, Italy (E.S., L. Mangoni); Medtronic Clinical Research Institute, Sesto San Giovanni, Italy (L. Manotta); and Humanitas Research Hospital, Rozzano-Milano, Italy (M. Gasparini).
Background: Three trials demonstrated recently that a long detection window reduces implantable cardioverter-defibrillator (ICD) therapy in primary prevention patients. Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) was the only trial that enrolled both primary and secondary prevention patients.
Methods And Results: Of the 1902 patients enrolled in the ADVANCE III trial, 477 received a defibrillator for secondary prevention; 248 patients were randomly assigned to a long detection setting (30 of 40 intervals) and 229 to the nominal setting (18 of 24 intervals) for ventricular arrhythmias with cycle length ≤ 320 ms.